In psoriasis, the keratinocyte proliferation that leads to skin lesions is a response to increased IL-17A production by memory Tc17 cells under the control of IL-23, providing an explanation for the efficacy of ustekinumab in this disease [23]. This evidence concerns the gene IL23A and psoriasis.